Comparative Pharmacology
Head-to-head clinical analysis: ATROPEN versus ATROPINE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPEN versus ATROPINE AUTOINJECTOR.
ATROPEN vs ATROPINE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5). Blocks parasympathetic nerve impulses, leading to increased heart rate, bronchodilation, decreased secretions, and mydriasis.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists.
0.5 to 1 mg IV/IM/SC every 3 to 5 minutes as needed; maximum 3 mg total. For bradycardia: 0.5 mg IV every 3-5 minutes to a maximum of 3 mg. For organophosphate poisoning: 2 mg IV/IM initially, then 2 mg every 5-10 minutes until atropinization.
2 to 4 mg intramuscularly (lateral thigh) or intravenously, repeated every 10-20 minutes if needed until muscarinic signs abate, maximum 3 doses.
None Documented
None Documented
Terminal half-life ~2-3 hours in adults; prolonged in elderly and infants due to reduced clearance.
Terminal elimination half-life: 2-4 hours (adults); prolonged to 6-12 hours in elderly or hepatic impairment.
Renal: ~50% unchanged; hepatic metabolism (hydrolysis) accounts for ~30-40%; fecal: <5%.
Renal: ~30-50% unchanged; hepatic metabolism: ~50%; fecal: minor.
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent